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Ezetimibe plus a Statin after Acute Coronary Syndromes
To the Editor: With regard to the article by 
Cannon et al. (June 18 issue),1 human serum 
cholesterol derives from two sources: it is either 
synthesized endogenously or absorbed in the in-
testine. Statins inhibit endogenous cholesterol 
synthesis, whereas ezetimibe inhibits intestinal 
cholesterol absorption.2 According to findings 
from the Scandinavian Simvastatin Survival Study3 
and the German Diabetes and Dialysis Study,4 
patients with a high level of cholesterol absorp-
tion may receive less benefit from statin therapy 
than those with a low level of cholesterol absorp-
tion. However, patients with elevated absorption 
may particularly benefit from the addition of 
ezetimibe to a statin regimen.2
Patients with elevated intestinal cholesterol 
absorption can be identified with genetic testing 
for risk alleles in the ATP-binding cassette trans-
porters G5 and G8 (ABCG5/8), Niemann–Pick C1–
like 1 (NPC1L1), and ABO genes.5,6 It remains to 
be investigated whether these alleles will predict 
whether statins will be less effective in reducing 
cardiovascular risk in patients harboring them 
than in those not harboring them. If so, testing 
for these alleles in addition to measuring low-
density lipoprotein (LDL) cholesterol levels may 
be helpful in deciding when to add ezetimibe 
treatment to ongoing statin therapy. This would 
be an approach toward personalized prevention 
of cardiovascular disease.
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To the Editor: We discussed the article by Can-
non et al. in a meeting of our internal medicine 
department. The rate of the primary end point 
was 2 percentage points lower in the simvastatin–
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ezetimibe group than in the simvastatin-mono-
therapy group, and the overall mortality was 
similar in the two groups. Of note, 42% of the 
participants in the Improved Reduction of 
 Outcomes: Vytorin Efficacy International Trial 
(IMPROVE-IT), regardless of treatment assignment, 
discontinued the study medication prematurely.
 We would like to know whether the authors 
conducted a per-protocol analysis, and in particu-
lar, whether there was a difference between pa-
tients who were adherent to therapy and those 
who were not, both within and between the as-
signed treatment groups, with respect to both 
the primary end point and mortality. It would 
also be interesting to know the mean LDL levels 
in these patients. These results could lead to a 
better understanding of the “lower is better” 
LDL hypothesis.
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To the Editor: IMPROVE-IT has aroused much 
enthusiasm among advocates of the concept of 
“lower is better,” and it will undoubtedly rekindle 
arguments in favor of targets for LDL cholesterol 
levels. Although these findings make a valuable 
contribution to this field, the benefit of ezeti-
mibe in this trial does not prove that the effect 
was mediated by the lowering of LDL cholesterol 
levels, nor does it provide support for the so-
called LDL hypothesis (i.e., that lowering the LDL 
cholesterol level results in a reduction in cardio-
vascular events). In fact, some studies have sug-
gested that ezetimibe may have pleiotropic effects, 
including amelioration of insulin resistance and 
antioxidant and antiinflammatory properties.1 
Furthermore, ezetimibe has been shown to have 
antiplatelet and antithrombotic effects that are 
independent of its effect on LDL cholesterol levels 
in patients with stable coronary artery disease.2 
These pleiotropic effects may account for at least 
some of the benefit of ezetimibe in further lower-
ing the risk of cardiovascular events.
The article by Cannon and colleagues appears 
to offer support for this ezetimibe hypothesis, 
since levels of high-sensitivity C-reactive protein 
were significantly lower in the simvastatin–
ezetimibe group than in the simvastatin-mono-
therapy group, and both groups consisted of 
patients with atherosclerotic vascular disease. 
Such a reduction has been shown to be indepen-
dent of changes in LDL cholesterol levels.3
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To the Editor: The patients in IMPROVE-IT 
had a higher baseline risk profile than that in 
patients in the Pravastatin or Atorvastatin Evalu-
ation and Infection Therapy–Thrombolysis in Myo-
cardial Infarction 22 (PROVE-IT–TIMI 22) study,1 
but in the IMPROVE-IT study, the incidence of 
cardiovascular events at 2 years was lower (19.0%, 
vs. 26.5%). This observation may reflect advanc-
es in the past decade in therapeutic strategies 
and risk-factor control after an acute coronary 
syndrome; it also strengthens the clinical rele-
vance of the absolute risk reduction afforded in 
IMPROVE-IT by the combination of ezetimibe plus 
simvastatin versus simvastatin alone, since it was 
obtained in an overall better-treated population.
In this trial, there was an absolute reduction 
of 5.5 percentage points in the primary end point 
at 7 years with ezetimibe plus simvastatin in pa-
tients with diabetes, as compared with 0.7 per-
centage points in those without diabetes. Given 
the specific prognostic role of triglycerides in 
patients with diabetes,2,3 the greater decrease in 
triglyceride levels at 1 year with the combination 
of ezetimibe plus simvastatin (to 120 mg per 
deciliter [1.4 mmol per liter] vs. 137 mg per deci-
liter [1.5 mmol per liter] in the simvastatin-
monotherapy group) might in part explain this 
difference in outcome. Specific analyses of the 
data on individual participants in the trial may 
help in answering this question.
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To the Editor: The trial reported in the article 
by Cannon et al. on the effects of the combina-
tion of simvastatin and ezetimibe in patients with 
a previous acute coronary syndrome is a land-
mark study, since a clear effect on the primary 
end point (which includes several cardiovascular 
end points) was reached with a nonstatin drug 
that was used in addition to a statin. However, 
this article shows, once again, that intensive low-
ering of LDL cholesterol levels (in this study, with 
simvastatin–ezetimibe) as compared with less 
intensive statin therapy, although useful from 
the standpoint of cardiovascular disease, does 
not lead to a decrease in mortality.1 This LDL-
cholesterol mortality paradox, as shown in Fig-
ure 1, is a reproducible phenomenon, and the 
article by Cannon et al. provides further strong 
support for the concept. In IMPROVE-IT, lower-
ing LDL cholesterol levels with intensive lowering 
of LDL cholesterol levels, as compared with the 
alternative therapy, did not decrease total mortal-
ity or cardiovascular mortality. This could mean 
that the cardiovascular events that were prevent-
ed were not severe enough to lead to the death of 
patients.
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To the Editor: IMPROVE-IT is interesting be-
cause it shows the difference between statistical 
significance and clinical relevance. In the trial, the 
addition of ezetimibe to simvastatin in patients 
with a recent acute coronary event was associated 
with a statistically significant reduction in the 
occurrence of a composite end point of death 
from cardiovascular disease, a major coronary 
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Figure 1. Odds Ratios for Mortality, According to Treatment for Cardiovascular Disease in Six Major Trials.
The meta-analysis was performed with the use of Comprehensive Meta-Analysis software, version 2.0 (Biostat). A random-effects analysis 
was carried out because of the heterogeneity of the data. The size of the squares corresponds to the number of patients with an event.  
A to Z denotes Aggrastat to Zocor, CI confidence interval, IDEAL Incremental Decrease in End Points through Aggressive Lipid Lowering, 
IMPROVE-IT Improved Reduction of Outcomes: Vytorin Efficacy International Trial, PROVE-IT–TIMI 22 Pravastatin or Atorvastatin 
Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22, SEARCH Study of the Effectiveness of Additional Reductions 
in Cholesterol and Homocysteine, and TNT Treating to New Targets. Data are from the studies listed in Nunes1 as well as from the article 
by Cannon et al.
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event, or nonfatal stroke after 7 years. However, 
the relative risk reduction was only 6%. Figure 2 
of the article by Cannon et al. shows that this 
difference is one of the smallest effects ever ob-
served in statin trials, even among three negative 
studies.1-3 The authors also did not mention the 
discordant findings of the ezetimibe-based Sim-
vastatin and Ezetimibe in Aortic Stenosis study.4
To show such a small difference, the investi-
gators had to include more than 18,000 patients 
with a very high baseline risk (35% for the pri-
mary outcome and 15% for death), although the 
number of patients screened for inclusion is not 
available. Even in these specific conditions, the 
absolute risk reduction was only 2 percentage 
points for the primary outcome and zero for 
death. We conclude that the addition of ezetimibe 
to simvastatin has little effect on cardiovascular 
risk and that this effect may be partly attribut-
able to a highly selected patient population.
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To the Editor: IMPROVE-IT shows that simva-
statin–ezetimibe combination therapy is superior 
to simvastatin monotherapy in lowering LDL 
cholesterol levels and decreasing cardiovascular 
risk among patients after myocardial infarction. 
The authors also point out that lowering LDL 
cholesterol levels below current target levels pro-
vides additional benefit. This statement was sup-
ported by the accompanying editorial,1 which 
suggests that all reductions in LDL cholesterol 
levels, regardless of whether they are from ezeti-
mibe or statins, are of equivalent benefit. How-
ever, an alternative approach is the use of high-
potency statins, as guidelines suggest.2
Our group previously compared the use of 
simvastatin monotherapy with simvastatin–
ezetimibe combination therapy and with high-
potency statins in 10,000 patients in the United 
Kingdom after myocardial infarction.3 We found 
a trend toward lower mortality when simvastatin–
ezetimibe combination therapy was compared 
with simvastatin monotherapy (hazard ratio, 0.93; 
95% confidence interval [CI], 0.62 to 1.38). 
However, when high-potency statin therapy was 
compared with simvastatin monotherapy, there 
was an even greater reduction in mortality of 
33% (hazard ratio, 0.67; 95% CI, 0.54 to 0.81); 
this effect was achieved with only modest aver-
age doses of atorvastatin (35 mg per day) and 
rosuvastatin (13 mg per day).
The adverse effects of statins are probably 
dose-related.4 Thus, we suggest that switching 
to a low-dose, high-potency statin be considered 
before adding a nonstatin agent.
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The Authors Reply: In response to Silbernagel 
and colleagues: data on the response to treat-
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ment with ezetimibe with respect to levels of LDL 
cholesterol have been very consistent across 
broad subgroups.1 Our analyses of serum sam-
ples are ongoing to test the hypothesis that pa-
tients with elevated intestinal cholesterol ab-
sorption have an enhanced response to ezetimibe, 
although one smaller prospective study did not 
provide support for this concept.2
In response to Couture et al.: an average of 
7% of patients per year discontinued the study 
drug; this rate is consistent with what has been 
observed in other long-term trials involving pa-
tients with cardiovascular and acute coronary 
syndromes. We conducted an on-treatment analy-
sis that was presented by Blazing3 at the scien-
tific sessions of the American Heart Association 
in 2014. As would be anticipated, the benefit of 
ezetimibe was greater across all the primary and 
secondary end points in this analysis.
Egom describes potential pleiotropic effects 
of ezetimibe. As we mentioned in the Discussion 
section of our article, we cannot determine 
whether, or to what degree, the clinical benefit 
seen when ezetimibe was added to simvastatin 
in IMPROVE-IT was mediated solely by the low-
ering of LDL cholesterol levels or to effects on 
high-sensitivity C-reactive protein, other lipopro-
teins such as triglycerides (as noted by Patti and 
Cavallari), or other potential pleiotropic effects. 
Given the quite striking concurrence of the 
IMPROVE-IT results with those of the Cholesterol 
Treatment Trialists meta-analysis (Fig. 2 of our 
article), we infer that the dominant effect of 
ezetimibe relates to lowering LDL cholesterol 
levels. The findings of recent genetic studies in 
which patients with polymorphisms of NPC1L1 
have both lower LDL cholesterol levels and a 
lower risk of coronary heart disease4,5 support 
this view.
Nunes noted a lack of an effect of ezetimibe 
on all-cause mortality. We were not surprised, 
since the size of our trial was not established to 
detect such an effect (which would have required 
approximately 40,000 patients). The degree of 
lowering of LDL cholesterol levels, by design, 
was smaller in IMPROVE-IT than in placebo-
controlled statin trials, only a minority of which 
showed such a mortality benefit. Nonetheless, 
the significant 13% relative reduction in the in-
cidence of myocardial infarction and the 21% 
relative reduction in the incidence of ischemic 
stroke are important clinical benefits associated 
with adding ezetimibe to a statin.
In response to the comment of Richard and 
colleagues: a key finding of our trial is that the 
clinical benefit is proportional to the extent of 
lowering of LDL cholesterol levels. We studied 
patients in whom the LDL cholesterol level while 
receiving a statin was “at goal” (<70 mg per 
deciliter [1.8 mmol per liter] on average) in order 
to explore whether an additional benefit could 
be seen with an LDL cholesterol level of approxi-
mately 55 mg per deciliter (1.4 mmol per liter) 
or less; thus, the difference in LDL cholesterol 
levels was modest. Patients with higher baseline 
LDL cholesterol levels would be expected to have 
a greater decrease in LDL cholesterol levels and 
a greater associated benefit.
Regarding the observational data from the 
registries cited by Singh et al., these data are hard 
to interpret because of confounding. As such, we 
prefer to look to randomized trials for treatment 
effects.
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